The size of the Antibodies Market in the Asia Pacific was valued at USD 12.95 Billion in 2020. This value is estimated to reach USD 20.73 Billion by the end of 2025, showcasing a growing potential of 9.87% CAGR during the forecast period.
The APAC region has the fastest growth rate of antibodies market in the world. The chronic disease burden of the region is increasing; thus, there is a rise in the research of monoclonal antibodies. The technological advancements and progressive R&D in the field of antibodies taking place in the Asia Pacific countries like India, China, Japan, and Australia are majorly expected to propel the market growth. Antibodies are used in research to develop new diagnoses and treatment for rare diseases and to study different biomarkers of different conditions. There is significant adoption of the therapeutic antibodies in this region, and the regulatory bodies in the area also have approved the treatment at a fast track without affecting safety. There are many antibody products in the clinical trials in the region, and the research been going in this region to create a vaccine for COVID-19 by using the antibody resistant to coronavirus.
The cost of antibody treatment is high, and the process is complex, which is restraining the Asia Pacific market growth to some extent. There are some side effects of the antibodies treatment like an allergic reaction, flu-like symptoms, vomiting, diarrhea, and low blood pressure, which is predicted to display a negative impact on the market to a limited extent. Less awareness in undeveloped countries is further degrading the market growth.
This research report has been segmented and sub-segmented into the following categories:
Regionally, the Indian antibodies market is growing at the highest rate in this region. The National Institute of Immunology (NII) has generated monoclonal antibodies for the detection of typhoid fever and hepatitis B virus. NII is also developing monoclonal antibodies against rotavirus and virulent strains of E. coli.
Chinese antibodies market was leading the Asia Pacific market in 2019. China has many institutes that are researching antibodies. China is trying to develop a vaccine for COVID-19.
The Japanese government is promoting the production of biosimilar using antibodies. Japan has also developed antibodies for anti-glycosaminoglycan.
Most promising companies operating in the APAC Antibodies Market Profiled in the Report are Abbott Diagnostics, Novartis AG, Pfizer Inc, ThermoFisher Scientific Inc, Eli Lilly and company, A.G. Scientific, Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, AbbVie Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product Type
5.1.1 Monoclonal Antibodies
5.1.1.1 Murine
5.1.1.2 Chimeric
5.1.1.3 Humanized
5.1.1.4 Human
5.1.2 Polyclonal Antibodies
5.1.2.1 Type I
5.1.2.2 Type II
5.1.2.3 Type III
5.1.2.4 Type IV
5.1.2.5 Type V
5.1.2.6 Type VI
5.1.2.7 Type VII
5.1.2.8 Type VIII
5.1.3 Antibody-Drug Complexes
5.1.3.1 Immunogen Technology
5.1.3.2 Seattle Genetics Technology
5.1.3.3 Immunomedics Technology
5.2 By Indication
5.2.1 Cancer
5.2.2 Autoimmune Diseases
5.2.3 Infectious Diseases
5.2.4 Cardiovascular Diseases
5.2.5 CNS Disorders
5.2.6 Others (Inflammatory, Microbial Diseases, & Other)
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
5.4 Application
5.4.1 Medical
5.4.2 Experimental
5.4.2.1 Western Blot
5.4.2.2 ELISA
5.4.2.3 Radioimmune Assays
5.4.2.4 Immunofluorescence
5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)
6. Geographical Analysis
6.1 Asia-Pacific
6.1.1 Introduction
6.1.2 China
6.1.3 India
6.1.4 Japan
6.1.5 South Korea
6.1.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Shimadzu Corporation (Japan)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 Thermo Fisher Scientific Inc. (U.S.)
9.5 Eli Lilly and Company (U.S.)
9.6 Takara Bio, Inc. (Japan)
9.7 Levena Biopharma (China)
9.9 F. Hoffmann-La Roche Ltd. (Switzerland)
9.10 Bio-Rad Laboratories, Inc. (U.S.)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
